ValGenesis

ValGenesis is a pharma-exclusive software vendor specializing in validation lifecycle management for GMP-regulated pharmaceutical and biotechnology manufacturing. Founded in 2005 by Dr. Siva Samy (CEO & Chief Product Strategist), the company pioneered the world's first digital validation lifecycle management system, transforming paper-based validation processes into fully digital workflows.

Headquartered in Santa Clara, California, ValGenesis serves 40 of the top 50 life sciences companies with 66,000+ users across 450+ GMP sites worldwide. The company has validated 100,000+ GMP systems using its cloud-based VLMS platform.

The company's flagship product, ValGenesis VLMS, provides comprehensive Computer System Validation (CSV), Computer System Assurance (CSA), and Critical Quality Verification (CQV) capabilities with AI-enabled automation modules. ValGenesis has remained focused exclusively on pharmaceutical and life sciences validation throughout its 20-year history.

ValGenesis is pharma-exclusive with 100% focus on pharmaceutical and life sciences validation. Serves 40 of top 50 life sciences companies with 66,000+ users across 450+ GMP sites. Notable customers include Bayer, Roche, Alexion, Strides, Philips Healthcare, Biocon, Dr. Reddy's Laboratories, Illumina, Catalent, Milliporesigma, Noven Pharmaceuticals, Transcat, and Rottendorf Pharma.

Customer base spans Big Pharma, biotech, CDMOs, and life sciences companies requiring GMP validation. VLMS platform built specifically for FDA CSA guidance with 21 CFR Part 11, EU Annex 11, PIC/S Data Integrity Guidance, and USFDA Data Integrity Guidance compliance. Customers report 90% reduction in validation-related audit observations and 100% audit readiness. Company has validated 100,000+ GMP systems with expertise in Computer System Validation (CSV), Computer System Assurance (CSA), and Critical Quality Verification (CQV) across pharmaceutical manufacturing environments.

Private company with conflicting revenue estimates: LeadIQ reports $300M annual revenue, Getlatka reports $22M (2024), Owler estimates $25M–$100M range. Total funding $24M–$40M across multiple sources. Most recent funding: $16M debt financing from Western Alliance Bank (July 2025). Additional historical funding includes equity and debt rounds, though exact amounts vary by source.

Company serves 66,000+ users across 450+ GMP sites with 40 of top 50 life sciences companies as customers. Validated 100,000+ GMP systems since founding in 2005. Continued investment in AI-enabled validation modules (iVal, iClean, iOps) and Process Lifecycle Suite expansion. No M&A activity or acquisition reported. Company maintains private ownership structure with Dr. Siva Samy as CEO and Chief Product Strategist since founding.

ValGenesis VLMS (Validation Lifecycle Management System) is the flagship product - world's first digital validation platform launched 2005. Cloud-based SaaS on Microsoft Azure providing comprehensive CSV, CSA, and CQV capabilities. Modular approach with AI-enabled automation modules: iVal (content generation), iClean (data integrity), iOps (automated test execution). Process Lifecycle Suite includes iCMC (chemistry/manufacturing/controls) and iCPV (continued process verification).

Platform features 100% digital validation with electronic signatures, tamper-proof audit trails, real-time multi-user authoring, and parallel workflows. Direct equipment integration via RS232 and TCP/IP. Automatic change impact assessment and offline execution capability. Innovation focus on AI-powered validation automation with real-time anomaly flagging during test execution. Built for FDA CSA guidance out of the box with support for ASTM, ISPE GAMP 5, and multiple data integrity guidances.

Cloud platform hosted on Microsoft Azure. Extensive API stack enables integration with ERP systems (SAP, Oracle), QMS platforms, MES systems, and laboratory equipment. Direct equipment integration via RS232 and TCP/IP protocols for validation testing.

Industry affiliations include support for ISPE GAMP 5 standards and ASTM compliance frameworks. Platform designed to integrate with existing pharmaceutical manufacturing technology stacks including quality management systems, enterprise resource planning, and manufacturing execution systems. Implementation and consulting partners are undisclosed.

Professional services include implementation support, system configuration for GMP environments, integration with existing systems, and user training programs. Training covers validation best practices, system administration, and AI module usage (iVal, iClean, iOps). Professional services available for validation strategy consulting, migration from legacy paper-based systems, and ongoing support.

Global support for 450+ GMP sites across multiple countries serving 66,000+ users. Customer testimonials describe rapid deployment using pre-built templates and validation documentation packages. Offline execution capability supports remote validation at manufacturing sites globally. Support hours, regional coverage, and certification programs are undisclosed.

Founded 2005 by Dr. Siva Samy who serves as CEO and Chief Product Strategist. Company pioneered the world's first digital validation lifecycle management system. Founder-led management for 20 years.

Market recognition includes serving 40 of top 50 life sciences companies with 66,000+ users and validation of 100,000+ GMP systems. Customer testimonials report 80% reduction in validation cycle time, 90% reduction in testing duration, and 90% reduction in validation-related audit observations. Listed on G2 with positive reviews. Built for FDA CSA guidance with 21 CFR Part 11 and EU Annex 11 compliance. ISO certifications, SOC 2 certification, and industry analyst awards are undisclosed.

Professional website highlights the VLMS platform, AI modules, and customer testimonials. Demo availability by request through sales team. Customer case studies showcase implementation results including validation cycle time reduction and audit readiness improvements. Product documentation covers CSV, CSA, CQV processes and AI-enabled automation capabilities.

Recent funding activity: $16M debt financing from Western Alliance Bank (July 2025). Listed on review platforms including G2 and GetApp. Market positioning as pharma-exclusive validation specialist serving 40 of top 50 life sciences companies. Website content frames the transition from paper-based to digital validation processes. Press release frequency, social media engagement metrics, and trial options are undisclosed.